6.54

2.03% 0.13

Aardvark Therapeutics Inc (AARD)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$6.41

Aprire:

$6.46

Volume 24 ore:

69,087

Relative Volume:

0.27

Capitalizzazione di mercato:

$143.13M

Reddito:

Utile/perdita netta:

$-69.87M

Rapporto P/E:

-2.0381

EPS:

-3.2089

Flusso di cassa netto:

$-61.75M

1 W Prestazione:

-17.22%

1M Prestazione:

+4.47%

6M Prestazione:

-45.95%

1 anno Prestazione:

-41.92%

Intervallo 1D:

$6.175

$6.8152

Intervallo di 1 settimana:

$6.175

$7.76

Portata 52W:

$3.35

$17.94

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Nome

Aardvark Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (604)

Telefono

(858) 225-7696

Indirizzo

4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-12

Ultimi documenti SEC

AARD's Discussions on Twitter

Compare AARD vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AARD Aardvark Therapeutics Inc	6.54	143.78M	0	-69.87M	-61.75M	-3.2089
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-02	Downgrade	H.C. Wainwright	Buy → Neutral
2026-03-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-03-02	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2026-03-02	Downgrade	Stifel	Buy → Hold
2026-01-28	Iniziato	B. Riley Securities	Buy
2025-12-23	Iniziato	Oppenheimer	Outperform
2025-12-12	Iniziato	William Blair	Outperform
2025-12-03	Iniziato	Raymond James	Strong Buy
2025-11-07	Iniziato	BTIG Research	Buy
2025-09-29	Iniziato	Stifel	Buy
2025-06-30	Iniziato	H.C. Wainwright	Buy
2025-03-10	Iniziato	BofA Securities	Buy
2025-03-10	Iniziato	Cantor Fitzgerald	Overweight
2025-03-10	Iniziato	Morgan Stanley	Overweight
2025-03-10	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie

01:12 AM

Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen - MarketBeat

01:12 AM

Aug 14, 2026

Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action - lincolnjournal.com

Aug 14, 2026

Aug 13, 2026

Aardvark Therapeutics Company Profile & Introduction - Moomoo

Aug 13, 2026

AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges - TipRanks

Aug 13, 2026

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits

Aug 13, 2026

Aug 12, 2026

Aardvark Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Morgan Stanley Maintains Aardvark Therapeutics(AARD.US) With Sell Rating, Maintains Target Price $3 - Moomoo

Aug 12, 2026

Why is Aardvark Therapeutics stock surging today? By Investing.com - Investing.com Canada

Aug 12, 2026

Why is Aardvark Therapeutics stock surging today? - Investing.com

Aug 12, 2026

Aug 11, 2026

Aardvark Therapeutics Q2 EPS of $(0.66) beats $(0.91) estimate - scanx.trade

Aug 11, 2026

Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria

Aug 11, 2026

Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash - Stock Titan

Aug 11, 2026

Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat

Aug 11, 2026

Aardvark Therapeut reports Q2 2026 results — $73.9M cash; net loss $14.4M - TradingView

Aug 11, 2026

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times

Aug 11, 2026

Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary - TradingView

Aug 11, 2026

Aardvark Reports $14.4 Million Q2 Net Loss as ARD-101 Hold Continues - quiverquant.com

Aug 11, 2026

AARD: Q2 2026 net loss was $14.4M; cash reserves support operations into late 2027 - TradingView

Aug 11, 2026

Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction - TradingView

Aug 11, 2026

Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions - quiverquant.com

Aug 11, 2026

Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026 - Stock Titan

Aug 11, 2026

Aug 07, 2026

Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 06, 2026

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits

Aug 06, 2026

Aug 05, 2026

Aardvark Therapeutics (AARD) Surges 5.8% as Biotech Names Draw Fresh AttentionHead and Shoulders - dars.gov.et

Aug 05, 2026

Aug 04, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Hold" by Brokerages - MarketBeat

Aug 04, 2026

Jul 30, 2026

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% LowerHagens Berman - PR Newswire

Jul 30, 2026

Jul 28, 2026